Aphria (APHA.TO) Stock Price
Aphria Price
Revenue has compounded at 296.8% per year over the past 5 years to 542.34 M CAD. Earnings per share have grown at 449.2% per year over the last 2 years. Aphria's net margin stands at -15.6%, down from 4.7% several years earlier.
Aphria stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Aphria business model & stock analysis
Frequently asked questions about Aphria
Aphria Inc is a renowned Canadian company operating in the cannabis industry. The business model of Aphria Inc revolves around the production, distribution, and sale of medical and recreational marijuana. With a focus on sustainable cultivation practices and innovative technologies, Aphria Inc has established itself as a leading player in the market. By leveraging its extensive expertise and partnerships, the company aims to meet the growing global demand for high-quality cannabis products. With a customer-centric approach, Aphria Inc strives to provide a wide range of offerings, including dried flowers, oils, vapes, and more. The company's commitment to delivering exceptional products and creating value for its shareholders sets it apart in the dynamic cannabis sector.
Aphria Inc is primarily active in the cannabis industry.
The main competitors of Aphria Inc in the market include Canopy Growth Corporation, Aurora Cannabis Inc, and Cronos Group Inc.
Aphria Inc is a leading Canadian cannabis producer founded in 2013. With headquarters in Leamington, Ontario, the company has established itself as a global player in the cannabis industry. Aphria cultivates, processes, and sells medical and recreational cannabis products for both the domestic and international markets. The company has a strong history of innovation and has consistently focused on sustainable production practices. Aphria's commitment to quality and patient care has earned it numerous accolades and certifications. As one of the largest Canadian cannabis companies, Aphria continues to expand its footprint and product offerings, driving growth and value for its shareholders.
Aphria Inc has achieved several significant milestones in its corporate history. The company successfully entered the Canadian recreational cannabis market with the legalization of adult-use cannabis in October 2018. Aphria expanded its global footprint by establishing key partnerships and acquisitions in various international markets. In 2019, the company became the first licensed producer to report positive adjusted EBITDA in Canada, showcasing its strong financial performance. Aphria's subsidiary, Broken Coast, won "Best Dried Flower" at the 2019 Canadian Cannabis Awards, further highlighting the company's commitment to product excellence. These achievements solidify Aphria Inc's position as a leading player in the cannabis industry.
Aphria Inc is primarily present in Canada, where it is headquartered. As a leading cannabis company, Aphria has established a strong footprint in the Canadian market, operating cultivation facilities and distribution channels across the country. With a focus on medical and recreational cannabis products, Aphria has gradually expanded its operations globally. It has also made strategic investments in countries like Germany, Argentina, Colombia, and Jamaica to tap into the international cannabis market. This multinational presence allows Aphria Inc to leverage diverse market opportunities and strengthen its position as a prominent player in the cannabis industry.
Aphria Inc represents a strong commitment to transparency, integrity, and sustainability. The company's corporate philosophy revolves around the principles of ethical business practices, social responsibility, and delivering high-quality products to its customers. Aphria aims to provide access to safe and affordable medical cannabis while adhering to strict regulatory standards. With a focus on innovation, research, and development, Aphria strives to lead the global cannabis industry by continuously improving its processes and products. By embodying these values, Aphria Inc aims to create long-term value for its shareholders and make a positive impact on the communities it serves.
Aphria Inc is a Canadian company that operates in the production and sale of medical marijuana. It has a strong presence in the Canadian market and also operates internationally. Aphria offers a wide range of products and services to its customers, including medical cannabis, wellness and beauty products, and retail operations. Aphria operates in three main business areas: the production of medical marijuana in various forms such as flowers, capsules, oils, and sprays; the operation of retail stores under the brand name "Meta Cannabis Co."; and the development of wellness and beauty products based on hemp under the brand name "Apothecary Botanicals". Through acquisitions and strategic partnerships, Aphria has expanded its market presence and is well positioned to grow in the expanding market for medical marijuana and related products.
The revenue cannot currently be calculated for Aphria.
The profit cannot currently be calculated for Aphria.
The P/E ratio cannot be calculated for Aphria at the moment.
The P/S cannot be calculated for Aphria currently.
The Eulerpool Quality Score for Aphria is 3/10.
The ISIN of Aphria is CA03765K1049. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Aphria is A12HM0. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Aphria is APHA.TO. The ticker symbol is used to trade Aphria shares on the stock exchange.
Aphria stock
Aphria Peer Group
Aphria FIGI
All fundamentals and in-depth analysis of Aphria
Our stock analysis for Aphria stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aphria. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.